Atlas Trials

Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL

Clinical trial NCT06530511 · UNKNOWN

Trial details

NCT number
NCT06530511
Sponsor
Affiliated Hospital of Nantong University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Lymphoma
Start date
2024-08-01
Primary completion
2026-02-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.